Vanda Pharmaceuticals (VNDA) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Oct 5, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $10.00 | Sep 23, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 from $21.00 | Aug 10, 2026 |
| B. Riley Securities | Maintained | Buy | $12.00 from $17.00 | Aug 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 from $24.00 | May 11, 2026 |
| Truist Securities | Initiated Coverage | Buy | $18.00 | Mar 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $24.00 from $22.00 | Feb 23, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $22.00 from $20.00 | Jan 5, 2026 |
| Jefferies | Maintained | Hold | $7.50 from $5.00 | Dec 31, 2025 |
| B. Riley Securities | Maintained | Buy | $14.00 from $11.00 | Dec 31, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Nov 19, 2025 |
| B. Riley Securities | Initiated Coverage | Buy | $11.00 | Nov 5, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $11.00 from $13.00 | Oct 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Aug 21, 2025 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $13.00 | May 14, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | May 7, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Apr 1, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 from $18.00 | Feb 18, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 | Feb 4, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 | Jan 28, 2025 |
Frequently asked questions
What is the price target for VNDA stock?
The average 12-month analyst price target for Vanda Pharmaceuticals (VNDA) is $14.00, with a high estimate of $20.00 and a low of $10.00, across 3 analysts.
Is VNDA a buy, sell, or hold?
Analysts covering Vanda Pharmaceuticals currently average a Buy rating: 3 buy, 1 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for VNDA?
The average price target of $14.00 implies 208.37% upside from the last price of $4.54.
What is the latest analyst rating on VNDA?
On Oct 5, 2026, HC Wainwright & Co. maintained Vanda Pharmaceuticals at Buy with a price target of $20.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.